Market Place
Sourcing Support
FDA Approves Phase II Clinical Trial For Ruxoprubart In ANCA Vasculitis
17 Jun 2024 //
GLOBENEWSWIRE
FDA Grants NM5072 Orphan Status For PNH Treatment
15 Apr 2024 //
GLOBENEWSWIRE
Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for PNH Treatment
12 Feb 2024 //
GLOBENEWSWIRE
USAN Approves Generic Name Ruxoprubart for NM8074
08 Jan 2024 //
GLOBENEWSWIRE
NovelMed Commences Phase II Trial for Anti-Bb Antibody (NM8074)
30 Oct 2023 //
GLOBENEWSWIRE
NovelMed Phase I Clinical Trial Shows Inhibition of the Alternative Pathway
05 Jun 2023 //
GLOBENEWSWIRE
Anti-Properdin Antibody Demonstrates Efficacy in Model of Wet-AMD and Dry-AMD
06 Mar 2023 //
GLOBENEWSWIRE
Anti-Bb Antibody Receives FDA Clearance to Start Trial in Naive aHUS Patients
30 Jan 2023 //
GLOBENEWSWIRE
NM3086 Reduced Hemolysis, LDH, in an Animal Model of PNH- a Rare Disease
12 Dec 2022 //
PRNEWSWIRE
Alternative Pathway Blocker NM8074 Receives FDA Clearance for Efficacy Trial
15 Aug 2022 //
PRNEWSWIRE
NovelMed reports interim positive data from Phase I trial of PNH asset
22 Feb 2022 //
CLINICALTRIALSARENA
NovelMed Announces Interim Positive Results from Its Phase I Trial of NM8074
21 Feb 2022 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.